Tag Archives: CELG

Best Blue Chip Stocks To Invest In Right Now


Fact: When interest rates rise, you need to be in dividend-growth stocks.

Proof: They’ve handily beaten the S&P 500 in the 17 months since the Federal Reserve put the zero-interest-rate era on ice.

In just a moment, I’ll show you 2 terrific off-the-radar dividend-growth plays to snap up now—and 2 surprising blue chips you’ll want to....More>>>

Hot Warren Buffett Stocks To Own For 2019

If you’re looking for good Warren Buffett stocks to buy, there’s no better option than Buffett’s former money guy. I’m talking, of course, about Lou Simpson, the long-time Geico portfolio manager, who retired at the end of 2010 after 31 years at the company, more than a third of them spent under Berkshire Hathaway Inc. (NYSE:BRK.A, NYSE:BRK.B) ownership.


Top 10 Undervalued Stocks For 2018

I believe Valero Energy (NYSE:VLO) shares are currently an undervalued long-term buy at current levels, based on its high free cash flow yield of over 10% and significant discount to its fair/intrinsic value. Additionally, I believe the company will continue to enjoy high returns on capital invested because of its sustainable competitive advantages. In this article I will explain the company’s....More>>>

Top 10 Undervalued Stocks To Invest In Right Now

Although you wouldnt necessarily know it from the relative performance of other banks in its weight class, Farmers Capital (NASDAQ:FFKT) has taken some meaningful self-improvement steps over the last couple of years. These moves have put the company on a path toward better interest spreads, better efficiency ratios, and better growth prospects, all of which should support higher earnings and returns....More>>>

day trading penny stocks

In this segment from the Motley Fool Money podcast, host Chris Hill is joined by Jason Moser of Million Dollar Portfolio, David Kretzmann of Hidden Gems Canada, and Aaron Bush of Motley Fool Rule Breakers to discuss the recent accounting woes at WageWorks (NYSE:WAGE). The provider of employee benefit plans has launched an investigation after reporting it inflated some of its profit and revenue figures.....More>>>

Top 5 Medical Stocks To Watch For 2018

Hospitals may soon have to post their standard prices for patients online, under a proposed rule unveiled Tuesday by the Trump administration.

Also, the administration is seeking comments on how to stop so-called surprise billing — when patients are charged after unknowingly being seen by out-of-network providers — and how to give patients better information about the out-of-pocket....More>>>

Top 10 Warren Buffett Stocks To Buy Right Now

Is volatilityfinally back! You bet your assets it is. The Dow fell well over 600 points into the closing bell, and the major equity indexes followed suit. As a reminder, investors have been stating openly that they wanted a big pullback so they could buy more of their favorite stocks. The only problem is that most retail investors usually freeze during sell-offs because they are scary while they....More>>>

Traders Sell Celgene (CELG) on Strength (CELG)

Investors sold shares of Celgene (NASDAQ:CELG) on strength during trading hours on Friday. $125.14 million flowed into the stock on the tick-up and $200.18 million flowed out of the stock on the tick-down, for a money net flow of $75.04 million out of the stock. Of all stocks tracked, Celgene had the 12th highest net out-flow for the day. Celgene traded up $2.16 for the day and closed at $84.54


Better Buy: Ziopharm Oncology, Inc. vs. bluebird bio Inc.

Chimeric antigen receptor T-cell (CAR-T) therapies and gene therapies are hot commodities these days. But some small biotechs developing CAR-T drugs and gene therapies are hotter than others.

Over the last 12 months, bluebird bio (NASDAQ:BLUE) stock has more than doubled. During the same period, Ziopharm Oncology’s (NASDAQ:ZIOP) share price has tumbled over 30%. That’s the past,....More>>>

3 Growth Stocks at Deep-Value Prices

Sometimes, earnings grow faster than stock prices. And other times,growth stocks go on sale even though revenue is still climbing. In both cases, P/E ratios can fall to levels that make growth stocks look more like value stocks. When that happens, buying shares can lead to market-beating returns, so we asked these three Motley Fool investors if there are any growth stocks on their radar that are....More>>>

bluebird bio Looks for Data Ahead

bluebird bio (NASDAQ:BLUE) reportedfirst-quarter earnings last week, but like the biotech typically does, management didn’t hold a conference call, which makes the earnings release more of a rehash of the quarter than an actual update.

Bluebird results: The only number that really matters


Q1 2018

Q4 2017

Quarter-Over-Quarter Change


Best Dividend Stocks To Buy For 2019

Target Corporation (TGT) offers a perfect buying opportunity to long-term investors, as the company continues to generate optimistic results, while strong operational and timely business strategies will allow it to outperform the market headwinds. Retailers have experienced significant losses in the first half this year due to rising inflation, increasing costs, mounting competition and tightening....More>>>

Are These 2 Biotech Laggards Ready to Rebound?

Biotech hasn’t been a great place to invest your money in 2018.The iShares Nasdaq Biotechnology Index, after all, is down by over 4% at present, and summer has historically been a down time for this high-risk space. So, there’s little reason to believe a widespread rally is coming anytime soon.

Even against this dour backdrop, however, several former top biotech stocks have turned....More>>>

10 Stocks To Watch For May 4, 2018

Some of the stocks that may grab investor focus today are:

Wall Street expects Celgene Corporation (NASDAQ: CELG) to report quarterly earnings at $1.96 per share on revenue of $3.46 billion before the opening bell. Celgene shares rose 1.87 percent to $87.00 in after-hours trading.
Weight Watchers International, Inc. (NYSE: WTW) reported stronger-than-expected results for its first....More>>>

Geron Bear V. Bull – 50垄 Or $50

Geron (GERN) is a tiny biotech, <$1 billion market cap, with an oversized history and an undersized pipeline. Its CEO has managed to steer the company through the wilderness within clear sight of the promised land. He expects that by Q3 2018, Johnson & Johnson’s (JNJ) subsidiary Janssen will make a long-awaited continuation decision as to whether it will proceed with development of....More>>>